Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tracy Wick

Adolescent Medicine Dayton, OH Medical Doctor

NPI 1174617203 CMS profile 795220

9000 North Main Street, Suite 332, Dayton, OH 45415

Open in the dashboard

General payments

$3,114

51 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tracy Wick of Dayton, OH is reported in the CMS Open Payments database as having received $3,114 across 51 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Adolescent Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $447 8
2024 General $457 15
2023 General $977 20
2022 General $214 3
2021 General $92 1
2020 General $37 1
2019 General $891 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tracy Wick
  • Adolescent Medicine median
  • Middle half of Adolescent Medicine
  • National median

In program year 2025, general payments to Tracy Wick were reported at $447. Among 914 Adolescent Medicine profiles paid that year, the median was $100 and the middle half received between $40 and $207.

Show as a table
Year Tracy Wick Adolescent Medicine median Middle half National median
2019 $891 $95 $36–$198 $163
2020 $37 $50 $23–$111 $114
2021 $92 $67 $27–$179 $132
2022 $214 $79 $29–$189 $149
2023 $977 $100 $39–$194 $160
2024 $457 $93 $38–$195 $164
2025 $447 $100 $40–$207 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $887 18 payments
  2. Eli Lilly and Company $707 1 payment
  3. Lilly USA, LLC $270 8 payments
  4. Organogenesis Inc. $212 5 payments
  5. Amgen Inc. $180 2 payments
  6. Pfizer Inc. $143 2 payments
  7. UCB, Inc. $138 2 payments
  8. E.R. Squibb & Sons, L.L.C. $125 1 payment
  9. Genzyme Corporation $103 1 payment
  10. Biofrontera Inc. $94 4 payments
  11. Other $254 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,406 50 payments
  2. Travel and Lodging $707 1 payment
Products named General payments · program years 2019–2025
  1. SKYRIZI $469 13 payments
  2. RINVOQ $310 4 payments
  3. Affinity $183 3 payments
  4. Otezla $180 2 payments
  5. TALTZ $173 7 payments
  6. OLUMIANT $172 7 payments
  7. CIBINQO $143 2 payments
  8. NOVACHOR $140 1 payment
  9. SOTYKTU $125 1 payment
  10. Cimzia $117 1 payment
  11. Other $616 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$1,096,736

Of which drugs: $987,601

Medicare patients

232

Average age 78

Services billed

43,677

102 women, 130 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 40%
Ischemic heart disease 21%
Atrial fibrillation 21%
Cancer 20%
Diabetes 17%
Chronic kidney disease 16%
Depression 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Affinity, per square centimeter Q4159 Office 61 2,317 $540,735
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 142 39,601 $53,057
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 28 70 $21,709

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Otezla
  • Amgen Inc. $97
$97 — —
TREMFYA
  • Janssen Biotech, Inc. $82
$82 — —
SKYRIZI
  • AbbVie, Inc. $67
$67 — —
Odomzo
  • Sun Pharmaceutical Industries Inc. $40
$40 — —
RINVOQ
  • AbbVie, Inc. $29
$29 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

51 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adolescent Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record